Berndt A. Modig
Director
Finance
Aurena Laboratories
Switzerland
Biography
Berndt A. Modig has been a member of our Board of Directors since April 2015. Mr. Modig was the Chief Financial Officer of Prosensa Holding N.V., a company dedicated to the development of treatments of neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy, from 2010 until it was sold to Biomarin. Prior to that, he was the Chief Financial Officer of Jerini AG, another publicly listed biotechnology company, and held various management positions in industry, finance and private equity groups. He started his professional career in the auditing practice of Price Waterhouse. He is a member of the Board of Directors and the Audit Committee of Affimed N.V., a member of the Board of Directors and chairman of the Audit Committee of Axovant Sciences, Ltd., a member and vice chairman of the Supervisory Board and chairman of the Audit Committee of Kiadis Pharma, and a member of the Board of Directors of Onco BioTek. Mr. Modig is a Certified Public Accountant and has an MBA from INSEAD.
Research Interest
Business Management
